{
    "nctId": "NCT02136927",
    "briefTitle": "Bioavailability Study of SPARC1210 and Reference1210 in Subjects With Metastatic Breast Cancer",
    "officialTitle": "N/A",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 33,
    "primaryOutcomeMeasure": "Maximum observed concentration (Cmax)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* The subject has given written, informed consent and is available for the entire study.\n* Histologically or cytologically confirmed diagnosis of breast cancer;\n* Locally recurrent or metastatic breast cancer for which taxane-based therapy is a rational treatment option;\n* Age 18 years or more\n\nExclusion Criteria:\n\n* Known hypersensitivity to both the study drugs or its excipients (Cholesteryl sulfate, Caprylic acid, Polyvinylpyrrolidone, Ethanol or Polyethylene glycol);\n* Presence of clinically evident active CNS metastases, including leptomeningial involvement, requiring steroid or radiation therapy;\n* Pre-existing clinically significant peripheral neuropathy (Grade 2 or higher according to CTCAE, Version 4.0);\n* Any other severe concurrent disease which in the judgment of the investigator would make the subject inappropriate for entry into this study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}